Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. director Joachim Kunkel was granted 633 shares of fully vested restricted stock on October 5, 2026; 75,328 shares were reported as directly held afterward. The award represented retainer fees he elected to receive in shares instead of cash and was based on an average trading price of $22.69 for Arteris common stock from August 24, 2026 through October 5, 2026. He elected to defer receipt of the shares.
Arteris, Inc. director Claudia F. Munce received a grant of 605 fully vested restricted shares on October 5, 2026, for retainer fees she elected to receive in common stock instead of cash. The grant was based on an average trading price of $22.69 per share for August 24 through October 5, 2026. Her direct holdings following the grant were 107,369 shares.
Arteris, Inc. (AIP) VP and General Counsel Paul L. Alpern sold 6,003 shares of common stock on October 5, 2026, at a weighted average price of $24.2379 per share. The shares were sold in multiple transactions at prices from $23.92 to $24.70. The sale was made under a Rule 10b5-1 trading plan adopted February 23, 2026; Alpern reported 61,082 directly held shares afterward.
Arteris, Inc. (AIP) director, President and CEO, and 10% owner K. Charles Janac sold 11,452 common shares on October 5, 2026, at a weighted average of $24.2741 per share; transactions ranged from $23.89 to $24.49. The sale was made under a Rule 10b5-1 trading plan adopted on December 12, 2025. Janac directly held 154,337 shares afterward. He was deemed to have voting and dispositive power over 8,129,071 shares held by Bayview Legacy, LLC, and served as trustee for the Charles and Lydia Janac Trust, which held 56,252 shares.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported selling 12,219 shares of common stock on October 5, 2026, at a weighted average price of $24.2880 under a Rule 10b5-1 plan adopted March 12, 2026; sale prices ranged from $23.89 to $24.64 inclusive. On October 2, 2026, four sales of 887, 1,931, 1,889 and 893 shares, each at $24.6431, were used to satisfy tax liability arising from restricted stock unit releases. The issuer's equity-plan election required these sell-to-cover transactions, which were not discretionary.
Arteris, Inc. officer Paul Alpern gave notice of a proposed sale of 2,003 common shares, with an aggregate market value of $49,393.98 and an approximate sale date of October 5, 2026. Morgan Stanley Smith Barney LLC is listed as broker, and the notice reports 49,152,102 shares outstanding. The transaction listing identifies NASDAQ as the exchange.
Arteris, Inc. (AIP) lists K. Charles Janac as the person whose account is associated with a proposed sale of 11,452 common shares, with an aggregate market value of $282,406.32 and an approximate sale date of October 5, 2026. Morgan Stanley Smith Barney LLC is listed as broker. The notice also records prior 10b5-1 sales by Bayview Legacy, LLC and K. Charles Janac from July 6 through October 1, 2026.
Arteris, Inc. (AIP) officer Laurent Moll reported a proposed sale of 32,713 common shares, with an aggregate market value of $806,702.58 and an approximate sale date of October 5, 2026. Morgan Stanley Smith Barney LLC is identified as the broker, and the notice reports 49,152,102 shares outstanding.
The securities table lists 3,000 shares under the Employee Stock Purchase Plan and 29,713 shares associated with Restricted Stock Units. Separately, the remarks state that the securities to be sold were acquired upon vesting of restricted stock units from April 1, 2024 through October 1, 2026.
Arteris, Inc. CEO K. Charles Janac reported a 100,000-share sale by Bayview Legacy, LLC on October 1, 2026, at a weighted average of $23.8239 per share. The sale was made under a 10b5-1 trading plan adopted by Janac as the LLC’s manager on December 12, 2025; Bayview Legacy held 8,129,071 shares afterward. On October 2, Janac reported four direct sales—2,775, 1,843, 1,966 and 2,775 shares—each at $24.6431 per share. The sales were to satisfy tax liability from restricted stock unit releases through mandated sell-to-cover transactions, not discretionary trades.
Arteris, Inc. (AIP) reported that its VP and General Counsel, Paul L. Alpern, exercised options on October 1, 2026, acquiring 4,000 common shares at $0.56 per share and 2,500 common shares at $9.28 per share. After those exercises, his reported option balances were 45,000 incentive stock options and 22,500 non-qualified stock options.
Alpern also sold 6,500 common shares on October 1 at a weighted average of $23.8359 per share, in multiple transactions priced from $23.41 to $24.15. The exercises and sale were reported as pursuant to a Rule 10b5-1 trading plan adopted February 23, 2026. On October 2, he sold four separate amounts—692, 765, 1,181 and 1,010 shares—each at $24.6431 per share, to satisfy tax liability from released restricted stock units under the issuer’s sell-to-cover requirement; those sales were not discretionary.